Human-CD123-targeting chimeric receptor ligand and application thereof
US11401317B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 31, 2017 |
| Grant date | Aug 2, 2022 |
| Priority date | — |
| Expiry date | Mar 9, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a human CD123-targeting chimeric receptor ligand, comprising an IL-3 molecule-based CD123 binding domain, a transmembrane region, and an intracellular signaling domain. The present invention provides a T cell modified by the human CD123-targeting chimeric receptor ligand and capable of specifically binding with CD123 on tumor cell surfaces, thereby having specific cytotoxicity on tumor cells. The present invention further relates to an application of the human CD123-targeting chimeric receptor ligand and an immune effector cell thereof in preparing an anti-tumor immunotherapy drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.